Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 17,717 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 17,717 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $18.69, for a total transaction of $331,130.73. Following the completion of the transaction, the chief financial officer directly owned 159,744 shares of the company’s stock, valued at approximately $2,985,615.36. The trade was a 9.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, June 22nd, Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $3,176,156.11.
• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $12.86, for a total value of $227,840.62.
• On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The shares were sold at an average price of $14.79, for a total value of $14,375.88.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $27,000.00.

Relay Therapeutics Price Performance

NASDAQ:RLAY opened at $19.63 on Thursday. The firm has a market capitalization of $3.76 billion, a price-to-earnings ratio of -12.50 and a beta of 1.67. The business has a 50 day simple moving average of $15.00 and a 200-day simple moving average of $11.81. Relay Therapeutics, Inc. has a 1 year low of $3.03 and a 1 year high of $20.20.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.58 million. As a group, analysts expect that Relay Therapeutics, Inc. will post -1.55 earnings per share for the current fiscal year.

Institutional Trading of Relay Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of RLAY. AQR Capital Management LLC lifted its position in shares of Relay Therapeutics by 11.9% during the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock worth $956,000 after purchasing an additional 38,812 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after purchasing an additional 5,238 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Relay Therapeutics in the 1st quarter worth about $53,000. Finally, Woodline Partners LP increased its stake in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after buying an additional 1,241,657 shares during the period. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RLAY. JPMorgan Chase & Co. started coverage on shares of Relay Therapeutics in a research report on Wednesday. They set an “overweight” rating and a $28.00 price objective on the stock. Barclays raised their target price on shares of Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Citizens Jmp lifted their price target on shares of Relay Therapeutics from $19.00 to $21.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 20th. Wall Street Zen raised shares of Relay Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, The Goldman Sachs Group raised their price objective on shares of Relay Therapeutics from $13.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Relay Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $23.73.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.